Standard and new treatments in cutaneous B-cell lymphomas
Version of Record online: 13 JAN 2006
Journal of Cutaneous Pathology
Volume 33, Issue Supplement s1, pages 47–51, February 2006
How to Cite
Dreno, B. (2006), Standard and new treatments in cutaneous B-cell lymphomas. Journal of Cutaneous Pathology, 33: 47–51. doi: 10.1111/j.0303-6987.2006.00544.x
- Issue online: 13 JAN 2006
- Version of Record online: 13 JAN 2006
- Accepted for publication November 5, 2005
Background: Primary cutaneous B-cell lymphomas (PCBCL) are cutaneous non-Hodgkin lymphomas and can be classified clinically and by prognosis. The aim of this paper is to perform a review of standard and new treatments.
Method: This paper provides a literature review of the different treatments of PCBCL.
Results: Surgery and radiotherapy remain the standard therapies in isolated cutaneous lesions. Systemic or intralesional interferon (IFN)-α may be an alternative in PCBCL with diffuse cutaneous lesions. In aggressive forms with poor prognosis, polychemotherapy is the first line of treatment although rituximab and radioimmunotherapy are evolving therapeutic options.
Conclusion: In the majority of cases, the treatment of CBCL is straightforward. In aggressive forms, new therapies and biologic therapies may be of real interest.